News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
15,921 Results
Type
Article (346)
Company Profile (1)
Press Release (15574)
Section
Business (8104)
Career Advice (6)
Deals (1127)
Drug Development (1072)
Employer Resources (3)
FDA (177)
Job Trends (417)
News (9821)
Policy (353)
Tag
Academia (23)
Allergies (2)
Alliances (361)
ALS (1)
Alzheimer's disease (31)
Antibody-drug conjugate (ADC) (2)
Approvals (188)
Artificial intelligence (4)
Autoimmune disease (3)
Bankruptcy (2)
Best Places to Work (421)
Biosimilars (1)
Bladder cancer (13)
Breast cancer (9)
Cancer (76)
Cardiovascular disease (8)
Career advice (5)
CAR-T (5)
CDC (1)
Cell therapy (13)
Cervical cancer (1)
Clinical research (947)
Collaboration (4)
Compensation (17)
COVID-19 (22)
CRISPR (1)
C-suite (1)
Cystic fibrosis (4)
Data (117)
Diabetes (9)
Diagnostics (181)
Digital health (3)
Diversity, equity & inclusion (1)
Drug discovery (3)
Drug pricing (1)
Duchenne muscular dystrophy (2)
Earnings (8107)
Editorial (1)
Employer resources (2)
Events (2110)
Executive appointments (2)
FDA (290)
Fibrodysplasia Ossificans Progressiva (1)
Funding (9)
Gene editing (2)
Gene therapy (5)
GLP-1 (15)
Government (62)
Grass and pollen (1)
Guidances (86)
Healthcare (578)
Huntington's disease (1)
IgA nephropathy (1)
Immunology and inflammation (3)
Indications (1)
Infectious disease (28)
Intellectual property (2)
Interviews (1)
IPO (911)
Job creations (18)
Job search strategy (5)
Layoffs (10)
Legal (49)
Lung cancer (14)
Lymphoma (6)
Management (2)
Manufacturing (1)
MASH (4)
Medical device (493)
Medtech (496)
Mergers & acquisitions (231)
Metabolic disorders (17)
Multiple sclerosis (1)
NASH (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (4)
Neuroscience (46)
NextGen: Class of 2026 (95)
Non-profit (51)
Obesity (4)
Ovarian cancer (1)
Pain (2)
Pancreatic cancer (3)
Parkinson's disease (5)
Patents (3)
Patient recruitment (4)
People (448)
Pharmacy benefit managers (1)
Phase 1 (274)
Phase 2 (380)
Phase 3 (378)
Pipeline (374)
Policy (1)
Postmarket research (29)
Preclinical (98)
Press Release (1)
Prostate cancer (4)
Radiopharmaceuticals (8)
Rare diseases (8)
Real estate (39)
Regulatory (279)
Research institute (39)
Resumes & cover letters (1)
Rett syndrome (1)
RSV (2)
Schizophrenia (5)
Series B (2)
Service/supplier (1)
Sickle cell disease (1)
Startups (24)
Supply chain (1)
Vaccines (11)
Weight loss (3)
Women's health (3)
Date
Last 7 days (17)
Last 30 days (38)
Last 365 days (956)
2026 (45)
2025 (947)
2024 (1089)
2023 (1257)
2022 (3812)
2021 (1330)
2020 (1245)
2019 (830)
2018 (682)
2017 (527)
2016 (411)
2015 (513)
2014 (318)
2013 (219)
2012 (267)
2011 (297)
2010 (275)
Location
Africa (2)
Alabama (1)
Arizona (5)
Asia (771)
Australia (64)
California (309)
Canada (103)
China (11)
Colorado (25)
Connecticut (12)
Delaware (29)
Europe (1989)
Florida (53)
Georgia (11)
Idaho (1)
Illinois (25)
India (1)
Indiana (20)
Japan (4)
Kansas (2)
Kentucky (1)
Louisiana (6)
Maine (7)
Maryland (44)
Massachusetts (174)
Michigan (9)
Minnesota (20)
Missouri (6)
Nevada (3)
New Hampshire (3)
New Jersey (116)
New York (77)
North Carolina (51)
Northern California (177)
Ohio (7)
Pennsylvania (92)
South America (20)
Southern California (110)
Tennessee (3)
Texas (43)
United States (1206)
Utah (17)
Virginia (3)
Washington State (42)
Wisconsin (4)
15,921 Results for "262".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy
The cornerstone of the deal is Ixo-vec, an intravitreal gene therapy currently in Phase III development for wet age-related macular degeneration. Eli Lilly made another foray into genetic medicine in June, picking up Verve Therapeutics for up to $1.3 billion.
October 24, 2025
·
2 min read
·
Heather McKenzie
Press Releases
Life Science Logistics Market to Reach USD 262.51 Billion by 2034, Drives Rising Demand for Biologics and Supply Chain Advancements
October 28, 2025
·
1 min read
Biotech Beach
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Spontaneous Urticaria
Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria.
October 12, 2023
·
3 min read
Drug Development
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Atopic Dermatitis
Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders, today announced that the first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of EP262 in subjects with atopic dermatitis (AD).
November 28, 2023
·
3 min read
Biotech Beach
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
Escient Pharmaceuticals announced that the first subject has been dosed in CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262 in subjects with chronic inducible urticaria.
September 25, 2023
·
4 min read
Press Releases
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
Sana Biotechnology, Inc. announced the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed CAR T therapy.
January 5, 2024
·
7 min read
Biotech Beach
Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in Inhibition of Mast Cell Degranulation in Multiple Species at the European Academy of Allergy and Clinical Immunology
Escient Pharmaceuticals today announced the presentation of preclinical data in multiple models of mast cell degranulation related to the company’s EP262 development program at the European Academy of Allergy and Clinical Immunology annual meeting being held in Hamburg, Germany, June 9-11, 2023.
June 8, 2023
·
3 min read
Drug Development
Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders
Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-inflammatory disorders, announced positive results from a Phase 1 first-in-human study of EP262, a potent, highly selective small molecule antagonist of MRGPRX2.
June 20, 2023
·
4 min read
Biotech Beach
Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting
Escient Pharmaceuticals announced the presentation of preclinical data in a mouse model of atopic dermatitis related to the company’s EP262 development program at the American Academy of Dermatology annual meeting being held in New Orleans, Louisiana, March 17-21, 2023.
March 16, 2023
·
3 min read
Drug Development
Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Pharmacology of EP262 at the American Academy of Allergy, Asthma and Immunology Annual Meeting
Escient Pharmaceuticals announced the presentation of preclinical data related to the company’s EP262 development program at the American Academy of Allergy, Asthma and Immunology Annual meeting being held in San Antonio, TX, February 24-27, 2023.
February 26, 2023
·
3 min read
1 of 1,593
Next
